ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028

Lifesciences | Diagnostic & Biotechnology

ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028

Market by Therapeutics, Diagnostics, and Country Outlook | Forecast 2022-2028

Request For Customization

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

As per Triton’s report, the Asia-Pacific Alzheimer’s disease therapeutics and diagnostics market is estimated to develop with a CAGR of 7.25% over the forecasting period 2022-2028.



Report scope can be customized per your requirements. Request For Customization 

The countries assessed in this region include:

•         South Korea

•         ASEAN Countries

•         India

•         China

•         Japan

•         Australia & New Zealand

•         Rest of Asia-Pacific

The market in this region is primarily driven by the ongoing population growth in developing nations like India, China, and Japan, which also raises the overall geriatric population. Individuals in the age group of 65 years and above are more vulnerable to neurological diseases like Alzheimer’s, which is expected to bolster the demand for AD therapeutics and diagnostics in the country.

As of 2019, there were 35.524 million individuals in Japan aged over 65 years, and this number is expected to rise to 37.278 million individuals by 2030, according to the World Aging 2019 report. The elderly are more likely to be affected by Alzheimer’s and other neurological diseases. The considered market is thus anticipated to progress in the near future as a result of this increased geriatric population.

The UN Population Fund’s 2017 report has estimated that, by 2030, nearly 1.7 million senior citizens in India would be affected by dementia. The growth in the economy has led to significant advancements in the Indian healthcare sector. Further, the growing prevalence of Alzheimer’s disease across the nation has increased the need for new medical technological developments for the early diagnosis and treatment of dementia and cognitive impairment. This is expected to foster the Alzheimer’s disease therapeutics and diagnostics market’s growth in the near future.

The original product manufactured by a pharmaceutical company is known as branded medicine. When a company produces a new medication, it must go through stringent testing and pass the evaluations to ensure that it is effective for treatment and safe for use. Pharmaceutical companies are granted exclusive manufacturing and distribution rights of these branded medicines as they make significant investments in the development of such medications.

The report assesses the market based on therapeutics and diagnostics. Here, the therapeutics segment comprises drug type, disease stage, and generic & branded. Generic & branded is further divided into generic and branded.

The eminent companies in the Alzheimer’s disease therapeutics and diagnostics market include Biogen Inc, Amarantus Bioscience Holdings Inc, Teva Pharmaceutical Industries Ltd, Baxter International Inc, Cognoptix Inc, Novartis AG, GE Healthcare, Merck and Co, and Pfizer Inc.

Eisai Co Ltd is a leading company that manufactures, distributes, and markets pharmaceuticals, with a strong focus on prescription drugs. It has 15 centers for clinical research, R&D, and drug discovery. Oncology and Neurology are the primary therapeutic areas of focus for the company. Its product, Aricept, is an oral donepezil medication aimed to treat dementia symptoms caused by Alzheimer’s disease (AD). Founded in 1941, Eisai Co Ltd is headquartered in Koishikawa Bunkyo-Ku, Japan.

 

Key deliverables of the report:

·       Market CAGR during the forecasting years 2022-2028

·       Detailed data highlighting key insights, industry components, and market strategies

·       Comprehensive information and estimation of the Alzheimer’s disease therapeutics and diagnostics market revenue growth in Asia-Pacific and its influence on the parent market

·       In-depth study of forthcoming trends in consumer behavioral patterns

·       A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces Model

·       A wide-ranging study of factors that will challenge the Asia-Pacific Alzheimer’s disease therapeutics and diagnostics market’s growth during the upcoming years

Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT
ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET 2022-2028
Lifesciences

ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET 2022-2028

Market by Type, Application, E ..

VIEW REPORT

Table of Content

1. ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – SUMMARY

2. INDUSTRY OUTLOOK

2.1. TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET

2.2. PHASES AND STERNNESS OF ALZHEIMER’S DISEASE

2.3. KEY INSIGHTS

2.3.1. USAGE OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE

2.3.2. R&D INVESTMENTS IN BIOMARKERS FOR EARLY DETECTION OF DEMENTIA

2.3.3. DEMAND FOR PERSONALIZED MEDICINES 

2.4. IMPACT OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET

2.5. PORTER’S FIVE FORCES ANALYSIS

2.6. MARKET ATTRACTIVENESS MATRIX

2.7. VENDOR SCORECARD

2.8. INDUSTRY COMPONENTS

2.8.1. RESEARCH & DEVELOPMENT (R & D)

2.8.2. RAW MATERIALS

2.8.3. MANUFACTURING

2.8.4. DISTRIBUTORS/WHOLESALERS/RETAILERS

2.8.5. END-USER

2.9. KEY IMPACT ANALYSIS

2.9.1. EFFECTIVENESS

2.9.2. PRICE

2.9.3. SAFETY

2.10. KEY MARKET STRATEGIES

2.10.1. ACQUISITIONS

2.10.2. PRODUCT LAUNCHES

2.10.3. CONTRACTS & AGREEMENTS

2.10.4. INVESTMENTS & EXPANSIONS

2.11. MARKET DRIVERS

2.11.1. PREVALENCE OF ALZHEIMER’S DISEASE

2.11.2. RISE IN THE ELDERLY POPULATION

2.12. MARKET CHALLENGES

2.12.1. FAILURE OF LATE-STAGE DRUGS

2.12.2. STRINGENT GOVERNMENT REGULATIONS

2.13. MARKET OPPORTUNITIES

2.13.1. EMERGENCE OF NEW DIAGNOSTIC TECHNOLOGIES

2.13.2. GROWING NUMBER OF PIPELINE DRUGS

3. ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY THERAPEUTICS

3.1. BY DRUG TYPE

3.1.1. MARKETED DRUGS

3.1.2. PIPELINE DRUGS

3.2. BY DISEASE STAGE

3.2.1. LATE STAGE: SEVERE AD

3.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.2.3. PRODROMAL STAGE

3.3. BY GENERIC & BRANDED

3.3.1. BRANDED

3.3.2. GENERIC

4. ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY DIAGNOSTICS

4.1. LUMBAR PUNCTURE TEST

4.2. POSITRON EMISSION TOMOGRAPHY

4.3. ELECTROENCEPHALOGRAPHY

4.4. MAGNETIC RESONANCE IMAGING

4.5. COMPUTED TOMOGRAPHY

4.6. BLOOD TEST

4.7. OTHER DIAGNOSTICS

5. ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – COUNTRY OUTLOOK

5.1. CHINA

5.2. JAPAN

5.3. INDIA

5.4. SOUTH KOREA

5.5. ASEAN COUNTRIES

5.6. AUSTRALIA AND NEW ZEALAND

5.7. REST OF ASIA-PACIFIC

6. COMPETITIVE LANDSCAPE

6.1. BAXTER INTERNATIONAL INC

6.2. F. HOFFMANN-LA ROCHE AG

6.3. ALLERGAN PLC (ACQUIRED BY ABBVIE)

6.4. NOVARTIS AG

6.5. PFIZER INC

6.6. SIEMENS HEALTHINEERS AG

6.7. AMARANTUS BIOSCIENCE HOLDINGS INC

6.8. EISAI CO LTD

6.9. ELI LILLY & COMPANY

6.10. LUPIN LIMITED

6.11. MERCK AND CO

6.12. BIOGEN INC

6.13. COGNOPTIX INC

6.14. GE HEALTHCARE

6.15. JOHNSON AND JOHNSON

6.16. SUN PHARMACEUTICALS INDUSTRIES LTD

6.17. TEVA PHARMACEUTICAL INDUSTRIES LTD

6.18. ZYDUS CADILA

7. METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE

7.2. SOURCES OF DATA

7.3. RESEARCH METHODOLOGY

List of Tables

TABLE 1: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)         

TABLE 2: MARKET ATTRACTIVENESS MATRIX      

TABLE 3: VENDOR SCORECARD       

TABLE 4: KEY STRATEGIC DEVELOPMENTS

TABLE 5: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)         

TABLE 6: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)   

TABLE 7: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)     

TABLE 8: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)       

TABLE 9: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)

TABLE 10: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

List of Figures

FIGURE 1: PORTER’S FIVE FORCES ANALYSIS

FIGURE 2: KEY IMPACT ANALYSIS

FIGURE 3: TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS

FIGURE 4: INDUSTRY COMPONENTS          

FIGURE 5: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021 & 2028 (IN %)

FIGURE 6: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2021 & 2028 (IN %)

FIGURE 7: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2028 (IN $ MILLION)

FIGURE 8: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2028 (IN $ MILLION)

FIGURE 9: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021 & 2028 (IN %)

FIGURE 10: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2022-2028 (IN $ MILLION)

FIGURE 11: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2028 (IN $ MILLION)

FIGURE 12: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2028 (IN $ MILLION)

FIGURE 13: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2021 & 2028 (IN %)

FIGURE 14: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $ MILLION)

FIGURE 15: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $ MILLION)

FIGURE 16: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2021 & 2028 (IN %)

FIGURE 17: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2028 (IN $ MILLION)

FIGURE 18: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2028 (IN $ MILLION)

FIGURE 19: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2028 (IN $ MILLION)

FIGURE 20: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2028 (IN $ MILLION)

FIGURE 21: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2028 (IN $ MILLION)

FIGURE 22: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN $ MILLION)

FIGURE 23: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2028 (IN $ MILLION)

FIGURE 24: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)    

FIGURE 25: CHINA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2022-2028 (IN $ MILLION)

FIGURE 26: JAPAN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2022-2028 (IN $ MILLION)

FIGURE 27: INDIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2022-2028 (IN $ MILLION)

FIGURE 28: SOUTH KOREA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2022-2028 (IN $ MILLION)

FIGURE 29: ASEAN COUNTRIES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2022-2028 (IN $ MILLION)  

FIGURE 30: AUSTRALIA & NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2022-2028 (IN $ MILLION)         

FIGURE 31: REST OF ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2022-2028 (IN $ MILLION)          

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying